Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (520)	3/29/2001 5:20:53 PM
From: Biomaven	Read Replies (1) \| Respond to of 656

Skeeter Bug - richard, you would be wise to consider mr snyder's point. bios are risky. Umm.. Rick (he doesn't answer to Richard) is one of the most experienced biotech investors in the US. Biotech fund managers and well-known analysts have been known to seek his advice. I assure you he does not need Mr Snyder's advice that biotechs are risky. (In fact Rick has had a remarkable record over the years of warning people away from biotechs that have subsequently crashed). Rick and other experienced biotech investors have always emphasized that you do need a basket of biotechs, so no argument there. Trusting the judgement of pharmas and tagging along only after they have entered the picture has generally not panned out well. In any event, the good biotechs are now only partnering very late in the game, or sometimes not at all. We've had a nice recovery here, but there's probably some ways to go yet. I'm hoping for a deal with someone with existing surplus capacity that will bring some more Enbrel capacity on-line ahead of the new plants. Peter